Global VRE and MRSA Antibiotics Market Trends, Business Overview, Industry Growth and Forecast to 2028

The global VRE and MRSA antibiotics market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period (2022-2028). VRE and MRSA antibiotics are the medication that can be used for the treatment of infection caused due to vancomycin-resistant enterococci (VRE) and methicillin-resistant staphylococcus aureus (MRSA). VRE and MRSA are antibiotic-resistant bacterias that can cause serious infections and can be spread due to contact. The major factor attributing to the growth of the global VRE and MRSA antibiotics market is the rising prevalence of MRSA infection. According to the Centers for Disease Control and Prevention (CDC), around 5% of the patients coming to hospitals in the US carry MRSA bacteria on their skin or in their nose. It is caused due to sharing of personal items including towels, razors that have been touched by the infected person.

Some major players in the market include Pfizer Inc., Sanofi SA, Eli Lilly & Co., Merck & Co. Inc., Xellia Pharmaceuticals ApS, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2019, Civica Rx, a nonprofit drug manufacturer and Danish Drugmaker entered into an agreement for the increased production of injected forms of vancomycin and daptomycin. The goal of this agreement is to increase the availability of these two short-supply antibiotics among patients that can be used for the treatment of VRE and MRSA infections.

(Get 15% Discount on Buying this Report)

Get Sample Copy of Global VRE and MRSA Antibiotics Market at:
https://orionmarketreports.com/request-sample/?id=96396&submit=Request+Sample%0D%0A

Market Coverage
• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

• Segment Covered-
o By Type
o By Distribution Channel

• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World

• Competitive Landscape- Pfizer Inc., Sanofi SA, Eli Lilly & Co., Merck & Co. Inc., and Xellia Pharmaceuticals ApS, among others.

Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

A full report of Global VRE and MRSA Antibiotics Market is available at:
https://orionmarketreports.com/global-vre-and-mrsa-antibiotics-market/96396/

Global VRE and MRSA Antibiotic Market Report by Segment

By Type
• Vancomycin
• Teicoplanin
• Linezolid
• Daptomycin

By Distribution Channel
• Hospital Pharmacies
• Retail Drug Stores

Global VRE and MRSA Antibiotic Market Report by Region
North America
• The US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa

Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.